Moore et al. 
Adrenalectomy + chemotherapy in advanced breast cancer
In most patients the subjective palliation involved a return to normal living.
Priestman and Baum 
Chemotherapy in advanced breast cancer
Toxicity is not related to the patients' age and diminished with successive courses of drugs.
Palmer et al. 
A single agent vs. five drug combination in node positive primary breast cancer
Better QOL in single agent group.
Coates et al. 
Intermittent vs. continuous chemotherapy in metastatic breast cancer
Continuous chemotherapy was better; changes in the QOL were independent prognostic factor of survival.
Kiebert et al. 
Peri-operative chemotherapy vs. no chemotherapy in early stage breast cancer
No differences 1 year after; patients considered chemotherapy most burdensome aspect of treatment.
Gelber et al. 
Single cycle of combination chemotherapy vs. longer duration chemotherapy for pre-menopausal or chemo-endocrine therapy for postmenopausal women
Better QOL in longer duration chemotherapy or chemo-endocrine therapy.
Berglund et al. 
Late effects of adjuvant chemotherapy vs. postoperative radiotherapy in pre- and post-menopausal breast cancer
Chemotherapy patients had higher overall QOL.
Richards et al. 
A (weekly for 12 courses vs. every three weeks for 4 courses) in advanced breast cancer
Similar survival but higher psychological distress in the three weeks group.
Hurny et al. 
CMF (6 cycles vs. 3 cycles) in operable breast cancer
QOL improved with increasing time from the study entry.
Campora et al. 
Adjuvant chemotherapy vs. palliative chemotherapy in metastatic breast cancer
No significant difference between groups.
Fraser et al. 
CMF vs. E in advanced breast cancer
Similar survival and no significant difference in overall global QOL.
Twelves et al. 
Iododoxorubicin in advanced breast cancer
Little evidence of benefit in terms of physical symptom relief, level of activity, psychological symptoms or global QOL.
Bertsch and Donaldson. 
Vinorelbine vs. melphalan
Vinorelbine was better in some aspects of QOL.
Swain et al. 
AC + G-CSF in node positive breast cancer
Tolerable physical symptoms and emotional distress.
McQuellon et al. 
High-dose chemotherapy + ABMT
No significant difference between pre- and post-treatment QOL.
Larsen et al. 
High-dose chemotherapy + ASCT
Resulting in poor physical and emotional health.
Hurny et al. 
6 cycles of CMF vs. 3 cycles CMF in node-positive operable breast cancer
Worse QOL during treatment but not after treatment completion.
Griffiths and Beaver 
High-dose chemotherapy in advanced breast cancer
No significant deterioration in QOL.
Lindley et al. 
Systemic adjuvant therapy
2–5 years after treatment good QOL. Small to modest gain was acceptable to women.
Ganz et al. 
TAM or chemotherapy alone or chemotherapy + TAM, or no adjuvant therapy
No significant differences in global QOL among treatment groups; those who received chemotherapy had more sexual problems and those who received TAM had more vasomotor symptoms.
Bernhard et al. 
Formestane vs. megestrol acetate in postmenopausal advanced breast cancer while on TAM
No significant difference in QOL; baseline QOL was strong predictive for QOL under treatment but not for time to treatment failure.
Fairclough et al. 
CAF vs. dose intensive a 16-week multi-drug regimen
Negative impact of the dose intensive 16-week regimen was observed, although Q-TwiST analysis showed a small gain for this regimen.
Osoba and Burchmore 
Trastuzumab (Hercptin) in metastatic breast cancer who may or may not have had prior chemotherapy
Trastuzumab was associated with an amelioration of the deleterious effects of chemotherapy alone; the drug was not associated with worsening of QOL.
McLachlan et al. 
Chemotherapy in metastatic breast cancer
QOL maintained or improved; patients did not want to trade quantity for QOL.
Macquart-Moulin et al. 
High-dose chemotherapy + G-CSF + ASCT in inflammatory breast cancer
QOL deterioration disappeared after treatment and returned to baseline after one year.
Riccardi et al. 
Doubling E within FEC vs. FEC in metastatic breast cancer
No significant difference in response or improvement of baseline QOL.
Kramer et al. [138, 139]
Paclitaxel vs. A in advanced breast cancer
QOL appeared to be prognostic for survival and response to treatment.
Joly et al. 
CMF + irradiation vs. irradiation in pre-menopausal breast cancer
Similar QOL was observed.
Hakamies-Blomqvist et al. 
T vs. sequential MF in metastatic breast cancer
Difference in QOL was minor favoring MF.
Broeckel et al. 
Adjuvant chemotherapy treated breast cancer (after 3 to 36 months)
Younger age, unmarried status, time since diagnosis and chemotherapy completion related to greeter depressive symptoms.
Carlson et al. 
High-dose chemotherapy + ASCT in metastatic breast cancer
Anxiety and depression continued to increase, loss of sexual interest, worrying and joint pain were reported.
Osoba et al. 
Chemotherapy + Trastuzumab (Hercptin) vs. Chemotherapy alone in metastatic breast cancer
More improved global QOL with chemotherapy + Herceptin.
Modi et al. 
Paclitaxel in metastatic breast cancer
QOL benefit in tumor response patients.
Heidemann et al .
Mitoxantrone vs. FEC in metastatic breast cancer
No significant difference in survival or response but a QOL scores favored mitoxantrone.
Genre et al. 
High-dose-intensity AC (21 vs. 14 days)
Shortening cycles had a high negative impact on QOL.
de Haes et al. 
Goserelin vs. CMF in peri-and pre-menopausal node-positive early breast cancer
Better QOL in favor of goserelin.
Brandberg et al. 
Tailored FEC vs. induction FEC followed with high-dose CTCb + peripheral SCT
No significant overall differences were found between groups.
Land et al. 
CMF vs. AC in axillary node negative and estrogen receptor negative breast cancer
Overall QOL was equivalent between two groups.
Fallowfield et al. 
ANA vs. TAM alone or in combination in postmenopausal early breast cancer
Similar overall QOL impact but some small differences in side effects profiles.
Bottomely et al. 
AT vs. AC in metastatic breast cancer
No significant differences in QOL between two groups.
Bernhard et al. 
TAM for 5 years or three prior cycles of CMF followed by 57 months TAM in estrogen receptor-negative and estrogen receptor-positive breast cancer
At completion there were no differences by treatment groups.
Tong et al. 
Capecitabine, idarubicin and cyclophosphamide (all-oral regimen, XIC) in metastatic breast cancer
No significant decease in global QOL scores.
Galalae et al. 
Radiotherapy and adjuvant chemotherapy vs. radiotherapy and hormonal therapy vs. radiotherapy alone after conserving surgery
Adjuvant chemotherapy lowered QOL vs. hormones or radiotherapy alone.
Elkin et al. 
Ovarian suppression vs. chemotherapy in pre-menopausal hormone-responsive breast cancer
Assuming equal efficacy ovarian suppression was superior. Efficacy would have impact on treatment choice.
Conner-Spady et al. 
High-dose chemotherapy + ABST in breast cancer with poor prognosis
Impaired QOL in short term but improved after 2 years.
Bottomley et al. 
Dose-intensives chemotherapy (CE + filgrastim) vs. CEF in locally advanced breast cancer
Groups did not differ in progression free survival; lower QOL in intensified group at short term but no difference at long term.
Ahles et al. 
Standard-dose systemic chemotherapy vs. local therapy only in long-term breast cancer survivors
Lower overall QOL in chemotherapy group.
Peppercorn et al. 
High-dose chemotherapy + ABMT vs. intermediate-dose chemotherapy in patients with stage II and III breast cancer
Patients who received more intensive therapy experienced transient declines in QOL; by 12 months after, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.
Semiglazov et al. 
CMF + mistletoe lectin (PS76A2) vs. CMF + placebo
PS76A2 improved QOL during and after chemotherapy.
Martin et al. 
FAC vs. TAC or TAC + G-CSF in node negative breast cancer
Lower QOL in patients treated with TAC. Addition of G-CSF improves QOL.
Hurria et al. 
Anthracyclin-based chemotherapy or CMF in older women with breast cancer
QOL maintained in both group.
Fallowfield et al. 
EXE vs. TAM after 2–3 years of TAM in postmenopausal primary breast cancer
Temporary decrease in overall QOL for EXE but no other differences.
Groenvold et al. 
CMF vs. ovarian ablation
CMF had more negative impact on QOL.
Cella et al. 
ANA vs. TAM alone or in combination in postmenopausal breast cancer
ANA and TAM had similar impact on QOL.
Liu et al. 
DPPE + A vs. A in patients with advanced or metastatic breast cancer
Patients on A alone had fewer disease and treatment adverse events and better QOL.
Karamouzis et al. 
Chemotherapy vs. supportive care in metastatic patients
QOL was better in patients receiving chemotherapy than those under supportive care.
Hopwood et al. 
QOL and mental health were favorable for most patients about to start radiotherapy but younger age and receiving chemotherapy were significant risk factors for poorer QOL.